JP2014207903A5 - - Google Patents

Download PDF

Info

Publication number
JP2014207903A5
JP2014207903A5 JP2014083444A JP2014083444A JP2014207903A5 JP 2014207903 A5 JP2014207903 A5 JP 2014207903A5 JP 2014083444 A JP2014083444 A JP 2014083444A JP 2014083444 A JP2014083444 A JP 2014083444A JP 2014207903 A5 JP2014207903 A5 JP 2014207903A5
Authority
JP
Japan
Prior art keywords
cancer
vector
pharmaceutical composition
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014083444A
Other languages
English (en)
Japanese (ja)
Other versions
JP5767733B2 (ja
JP2014207903A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014207903A publication Critical patent/JP2014207903A/ja
Publication of JP2014207903A5 publication Critical patent/JP2014207903A5/ja
Application granted granted Critical
Publication of JP5767733B2 publication Critical patent/JP5767733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014083444A 2007-02-28 2014-04-15 ブラキュリポリペプチドおよび使用方法 Active JP5767733B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90423607P 2007-02-28 2007-02-28
US60/904,236 2007-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009551830A Division JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法

Publications (3)

Publication Number Publication Date
JP2014207903A JP2014207903A (ja) 2014-11-06
JP2014207903A5 true JP2014207903A5 (enExample) 2015-05-14
JP5767733B2 JP5767733B2 (ja) 2015-08-19

Family

ID=39650527

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009551830A Active JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法
JP2014083444A Active JP5767733B2 (ja) 2007-02-28 2014-04-15 ブラキュリポリペプチドおよび使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009551830A Active JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法

Country Status (7)

Country Link
US (3) US8188214B2 (enExample)
EP (3) EP2918598B1 (enExample)
JP (2) JP5596980B2 (enExample)
AU (1) AU2008221383B2 (enExample)
CA (1) CA2678404C (enExample)
DK (1) DK2918598T3 (enExample)
WO (1) WO2008106551A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105821078A (zh) * 2010-12-09 2016-08-03 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
SG193396A1 (en) 2011-03-17 2013-10-30 Globeimmune Inc Yeast-brachyury immunotherapeutic compositions
ES2752190T3 (es) * 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
WO2014043535A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
KR20150132867A (ko) * 2013-03-19 2015-11-26 글로브이뮨 척색종에 대한 효모-기반의 면역치료
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
US11753652B2 (en) * 2015-07-31 2023-09-12 Bavarian Nordic A/S Cassette encoding a FPV/brachyury fusion protein
JP6789283B2 (ja) 2015-08-03 2020-11-25 グローブイミューン，インコーポレイテッド 改変酵母−ブラキュリー免疫療法組成物
EP4137150A1 (en) 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
EP3400009A2 (en) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
SG11201810631SA (en) * 2016-06-03 2018-12-28 Etubics Corp Compositions and methods for tumor vaccination using prostate cancer-associated antigens
KR20190034160A (ko) * 2016-06-03 2019-04-01 이투빅스 코포레이션 Her2/neu 가 관련되는 종양 백신화 및 면역요법을 위한 조성물 및 방법
JP7340458B2 (ja) 2017-05-09 2023-09-07 アメリカ合衆国 Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ
CN114829882B (zh) 2019-11-05 2023-02-28 阿比尔技术公司 植物产品中感染的预测
WO2022187963A1 (en) * 2021-03-10 2022-09-15 Provincial Health Services Authority Immunotherapy agents targeting brachyury and methods of using same
CN121186374A (zh) * 2025-09-19 2025-12-23 北京大学第三医院（北京大学第三临床医学院） 一种用于脊索瘤检测的试剂盒及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
CA1340456C (en) 1986-07-07 1999-03-23 Hubert J.P. Schoemaker Chimeric rodent/human immunoglobulins specific for tumor-associated antigens
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0278940A3 (en) 1987-01-30 1988-12-07 Smithkline Biologicals S.A. Hepatitis b virus surface antigens and hybrid antigens containing them
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
DE10399031I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
CA1340203C (en) 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
US5543508A (en) 1987-12-15 1996-08-06 Gene Shears Pty. Limited Ribozymes
WO1990001069A1 (en) 1988-07-20 1990-02-08 Segev Diagnostics, Inc. Process for amplifying and detecting nucleic acid sequences
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
WO1991019803A1 (en) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
ATE166578T1 (de) 1991-07-25 1998-06-15 Idec Pharma Corp Anregung von antworten zytotoxischer t- lymphozyten
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
EP0630234B1 (en) 1992-03-12 1997-06-11 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
WO1993023569A1 (en) 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
EP1251170A3 (en) 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of NF-kappaB dependent animal diseases
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
EP0776376B1 (en) 1994-07-15 2001-11-21 Akzo Nobel N.V. Use of rna polymerase to improve nucleic acid amplification process
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
WO1996010419A2 (en) * 1994-10-03 1996-04-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
EP0814184A4 (en) 1995-02-14 1999-04-14 Chisso Corp BIODEGRADABLE FIBER AND NONWOVEN TEXTILE
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
EP1012276A2 (en) * 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
JP2001510808A (ja) 1997-07-24 2001-08-07 イネックス ファーマシューティカルズ コーポレイション 核酸触媒の供給のためのリポソーム組成物
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
AU1606799A (en) * 1997-12-09 1999-06-28 Virogenetics Corporation Recombinant vaccinia constructs expressing feline il-2, compositions and methodsof use thereof
CA2315256A1 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6849255B2 (en) * 1998-08-18 2005-02-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for enhancing cartilage repair
ATE370234T1 (de) 1998-09-01 2007-09-15 Us Gov Health & Human Serv Page-4, ein gage-ähnliches gen auf dem x- chromosom das von neoplastischer prostata, testis und uterus exprimiert wird, und dessen anwendungen
PL201881B1 (pl) * 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US20020131976A1 (en) * 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
JP2002537828A (ja) 1999-03-10 2002-11-12 フォゲン リミティド 細胞への物質のデリバリー
IL147507A0 (en) * 1999-07-13 2002-08-14 Us Gov Health & Human Serv T-cell receptor y and uses thereof
EP1218030A4 (en) 1999-09-10 2004-09-15 Univ Fordham METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING TRANSPLANT REJECTION BY USING HEAT SHOCK PROTEINS
JP2003531865A (ja) * 2000-04-28 2003-10-28 アメリカ合衆国 Ｄｎａおよびワクシニアウイルスベクターワクチンの組み合わせを用いた免疫原性の改善
WO2002078516A2 (en) * 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
AU2002330714A1 (en) * 2001-05-30 2003-01-02 Biomedical Center In silico screening for phenotype-associated expressed sequences
SG145559A1 (en) * 2002-06-06 2008-09-29 Oncotherapy Science Inc Genes and polypeptides relating to human colon cancers
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20090144209A1 (en) * 2004-07-07 2009-06-04 Nec Corporation Sequence prediction system
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes

Similar Documents

Publication Publication Date Title
JP2018148890A5 (enExample)
JP6794442B2 (ja) 新規な遺伝子組換えワクシニアウイルス
KR102684237B1 (ko) 개인 맞춤형 백신
JP2021535749A5 (enExample)
JP2020530303A (ja) Ｃａｒ ｔ細胞標的を発現する腫瘍溶解性ウイルス、及びその使用
US20120121617A1 (en) Promoters for recombinant viral expression
JP2015533841A5 (enExample)
SG10201809075XA (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
JP2010259446A5 (enExample)
JP2016510989A5 (enExample)
JP2010519904A5 (enExample)
CN105829537B (zh) 用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体
JP2019535311A5 (enExample)
CA3031416A1 (en) Recombinant vaccinia virus and use thereof
JP2018521651A5 (enExample)
JP2019500907A5 (enExample)
RU2019112725A (ru) Композиции и способы для повышения стабильности трансгенов в поксвирусах
JP6235697B2 (ja) 変異ワクシニアウイルス株、その使用およびそれを作製する方法
JP2023503858A (ja) ４－１ｂｂｌアジュバント添加した組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）の医学的使用
JP2015520178A5 (enExample)
JP2021528367A5 (enExample)
JP2025500867A (ja) 前立腺癌ワクチン及びその使用
CN103484462B (zh) Survivin启动子调控CD基因的重组腺病毒载体构建及其应用
JP2022552377A5 (enExample)
Lousberg et al. Innate immune recognition of poxviral vaccine vectors